Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CVSINASDAQ:DRRXNASDAQ:LIANOTCMKTS:PVOTF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSICV Sciences$0.04+7.1%$0.03$0.02▼$0.06$6.80M0.6233,929 shs105,100 shsDRRXDURECT$0.64-4.0%$0.61$0.48▼$1.74$20.70M0.6440,657 shs88,520 shsLIANLianBio$0.43+3.2%$0.33$0.27▼$4.99$46.82M0.231.04 million shs4,087 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSICV Sciences+7.07%+6.49%+55.12%+30.46%-29.64%DRRXDURECT-4.00%+0.76%+18.30%-20.00%-51.15%LIANLianBio0.00%+5.68%+16.73%+116.65%+39.77%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVSICV SciencesN/AN/AN/AN/AN/AN/AN/AN/ADRRXDURECT0.5424 of 5 stars0.02.00.04.41.10.00.0LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVSICV Sciences 0.00N/AN/AN/ADRRXDURECT 2.00HoldN/AN/ALIANLianBio 0.00N/AN/AN/APVOTFBetterLife Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVSICV Sciences$15.70M0.46N/AN/A$0.01 per share3.94DRRXDURECT$1.86M10.70N/AN/A$0.29 per share2.21LIANLianBioN/AN/AN/AN/A$2.71 per shareN/APVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVSICV Sciences-$2.39MN/A0.00∞N/A-12.25%-89.43%-22.75%N/ADRRXDURECT-$8.32M-$0.15N/AN/AN/A-91.54%-267.36%-64.00%8/12/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/APVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVSICV SciencesN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVSICV Sciences0.261.140.30DRRXDURECTN/A1.231.22LIANLianBioN/A10.0610.06PVOTFBetterLife PharmaN/A3.623.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVSICV SciencesN/ADRRXDURECT28.03%LIANLianBio74.85%PVOTFBetterLife PharmaN/AInsider OwnershipCompanyInsider OwnershipCVSICV Sciences1.30%DRRXDURECT3.20%LIANLianBio7.59%PVOTFBetterLife Pharma34.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVSICV Sciences70184.79 million182.39 millionNot OptionableDRRXDURECT8031.04 million30.05 millionOptionableLIANLianBio110108.06 million99.86 millionNot OptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableCVSI, PVOTF, DRRX, and LIAN HeadlinesRecent News About These CompaniesBetterLife Pharma Inc.May 19, 2025 | barrons.comBetterLife appoints Steven Sangha to board of directorsApril 1, 2025 | markets.businessinsider.comBetterLife Pharma Achieves Key Cardiac Safety MilestoneNovember 25, 2024 | markets.businessinsider.comBetterLife Pharma Inc BETRNovember 2, 2024 | morningstar.comMOptimistic Buy Rating for BridgeBio Pharma’s BBP-812: Promising Phase 1/2 Results in Canavan Disease TherapyOctober 25, 2024 | markets.businessinsider.comBridgeBio Pharma’s BBP-812 Trial Shows Promise for Canavan Disease Amidst Focus on AcoramidisOctober 25, 2024 | markets.businessinsider.comBetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001October 23, 2024 | tmcnet.comWith election nearing, BMO analysts don't expect major pharma shake-ups from either candidateOctober 14, 2024 | fiercepharma.comFAbortion, immigration, drug prices: Where Missouri’s candidates for U.S. Senate stand on the issuesOctober 13, 2024 | msn.comDemocrats snatch a major political football away from Republicans: freedomAugust 28, 2024 | yahoo.comRAMM Pharma Corp. (RAMM.CN)August 22, 2024 | uk.finance.yahoo.com‘Their skin was peeling off from the chemical burns’: Andhra reactor blast that killed 14 leaves trail of broken homesAugust 21, 2024 | indianexpress.comIRewarding careers for animal loversAugust 13, 2024 | deccanherald.comDState, city leaders announce deal for quantum technology facility on Chicago’s South SideJuly 27, 2024 | courthousenews.comC$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management DrugsApril 26, 2024 | msn.comJardiance and Ofev propel Boehringer’s human pharma salesApril 17, 2024 | msn.comVertex Pharma scientist talks about the long road to developing non-addictive painkillersApril 15, 2024 | abcnews.go.comPharmacy defends Eli Lilly off-label drug suitApril 11, 2024 | lifesciencesipreview.comLBetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 11, 2024 | tmcnet.comVictory Over Big Pharma Will Take More Than the IRAApril 4, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVSI, PVOTF, DRRX, and LIAN Company DescriptionsCV Sciences OTCMKTS:CVSI$0.04 +0.00 (+7.07%) As of 07/7/2025 03:58 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.DURECT NASDAQ:DRRX$0.64 -0.03 (-4.00%) As of 07/7/2025 04:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.LianBio NASDAQ:LIAN$0.43 +0.01 (+3.17%) As of 07/3/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.BetterLife Pharma OTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
